Abstract / Description of output
To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial.
Original language | English |
---|---|
Pages (from-to) | 1954-60 |
Number of pages | 7 |
Journal | Journal of Clinical Oncology |
Volume | 31 |
Issue number | 16 |
DOIs | |
Publication status | Published - 1 Jun 2013 |
Keywords / Materials (for Non-textual outputs)
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Carcinoma, Lobular
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Invasiveness
- Proportional Hazards Models
- Receptor, erbB-2
- Receptors, Estrogen
- Receptors, Progesterone
- Survival Analysis
- Treatment Outcome
- Tumor Markers, Biological